重组人血管内皮抑制素 (先声药业)(Recombinant Human Endostatin (Simcere)) - 药物靶点：VEGFR_在研适应症：非小细胞肺癌，恶性腹水，恶性胸腔积液_专利_临床

概要

基本信息

药物类型

重组蛋白

别名

Endostar、Endu、rh-endostatin

+ [2]

靶点

VEGFR

作用机制

VEGFR拮抗剂(血管内皮细胞生长因子受体拮抗剂)

治疗领域

癌症呼吸系统疾病其他疾病

在研适应症

非小细胞肺癌恶性腹水恶性胸腔积液+ [1]

非在研适应症

晚期结直肠腺癌晚期肺腺癌脑转移瘤+ [3]

原研机构

先聲藥業集團有限公司

在研机构

山东先声生物制药有限公司

非在研机构

江苏先声药业有限公司

最高研发阶段批准上市

首次获批日期

中国 (2005-09-12),

非小细胞肺癌

最高研发阶段(中国)批准上市

特殊审评-

登录后查看首次获批时间轴

序列信息

Sequence Code 720094457

关联

96

项与重组人血管内皮抑制素 (先声药业) 相关的临床试验

ChiCTR2400088085 / Suspended早期临床1期IIT

Efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma

开始日期2024-08-20

申办/合作机构-

NCT06562673 / Not yet recruiting临床1/2期IIT

Efficacy and Safety of Intra-arterial Cisplatin Plus Anti-angiogenesis Inhibitor Rh-endostatin (Endostar) Combined With Systematic Chemotherapy in Osteosarcoma

The goal of this clinical trial is to learn the efficacy and safety of intra-arterial cisplatin plus anti-angiogenesis inhibitor rh-endostatin (Endostar) combined with systematic chemotherapy in osteosarcoma. The main questions it aims to answer are:
* Is it safe when rh-endostatin and cisplatin are administered intra-arterially?
* Does intra-arterial cisplatin plus rh-endostatin increase the rate of tumor necrosis compared with traditional treatment?
Researchers will treat newly diagnosed osteosarcoma patients with systematic treatment and local treatment.
For systematic treatment, regular high-dose methotrexate and adriamycin will be administered intravenously.
For local treatment, rh-endostatin was administered intra-arterially with dosage of 150 mg for a 6-h continuous infusion; then cisplatin was administered intra-arterially at 120 mg/m2 as a 6-h continuous infusion.
Local treatment is conducted by insertion of a catheter percutaneously using the Seldinger technique through the brachial or femoral artery under local anesthesia.
Participants will:
• Receive local combined with systematic treatment once every 2-3 weeks for 2-4 cycles before surgery.

开始日期2024-08-20

申办/合作机构-

ChiCTR2400085777 / Suspended临床4期IIT

A multicenter real-world study on the efficacy and safety of recombinant human endostatin combined with chemotherapy and PD-1/PD-L1 first-line treatment in non-surgical NSCLC patients

开始日期2024-06-21

申办/合作机构-

100 项与重组人血管内皮抑制素 (先声药业) 相关的临床结果

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的转化医学

登录后查看更多信息

100 项与重组人血管内皮抑制素 (先声药业) 相关的专利（医药）

登录后查看更多信息

473

项与重组人血管内皮抑制素 (先声药业) 相关的文献（医药）

2024-08-01·European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery

Anti-angiogenesis agents plus chemoradiotherapy for locally advanced nasopharyngeal cancer: a systematic review and meta-analysis

Review

作者: Xin, Yong ; Lou, Yufei ; Zhu, Youqi ; Sun, Xueqing ; Lu, Xinyu ; Guo, Yilong ; Wang, Bo ; Yu, Dehong

PURPOSE:

To evaluate literature evidences about the efficacy and safety of anti-angiogenesis agents plus chemoradiotherapy versus chemoradiotherapy in the treatment of locally advanced nasopharyngeal carcinoma.

METHODS:

The relevant literature was systematically searched from the date of establishment to April 2023 in PubMed, Embase, Web of Science, The Cochrane Library, Chinese National Knowledge Infrastructure, Chinese Biological Medicine, Wanfang and VIP database. Search terms included: Nasopharyngeal Neoplasms, Angiogenesis inhibitors, Endostar, Anlotinib, Apatinib, Bevacizumab, Sunitinib, Pazopanib, Chemoradiotherapy. The literature was strictly screened according to the inclusion and exclusion criteria, and 8 eligible studies were finally included in our meta-analysis (4 randomized controlled trials and 4 retrospective studies).

RESULTS:

A total of 642 patients were included, with 316 in the anti-angiogenesis agents plus chemoradiotherapy group and 326 in the chemoradiotherapy group. The results of our meta-analysis showed that compared with chemoradiotherapy group, the complete response rate (RR = 1.35, 95% CI 1.05-1.74, P = 0.02), objective response rate (RR = 1.26, 95% CI 1.12-1.43, P = 0.0002) in the anti-angiogenesis agents plus chemoradiotherapy group were significantly improved. In terms of safety, there was a higher incidence of cardiac arrhythmia (RR = 3.63, 95% CI 1.16-11.37, P = 0.03) and hypertension (RR = 1.85, 95% CI 1.04-3.27, P = 0.004) in the anti-angiogenesis agents plus chemoradiotherapy group, while no statistically significant differences were reported in other adverse reactions (all P > 0.05).

CONCLUSION:

Compared with chemoradiotherapy, anti-angiogenesis agents plus chemoradiotherapy could bring more benefits in terms of short-term efficacy, particularly by notably improving both complete response rate and objective response rate, and overall adverse reactions were acceptable. Anti-angiogenesis agents plus chemoradiotherapy may provide a promising direction for the treatment of locally advanced nasopharyngeal carcinoma.

SYSTEMATIC REVIEW REGISTRATION:

https://inplasy.com/inplasy-2023-8-0076/ , registration number INPLASY202380076.

2024-06-01·Cancer Medicine

Immunotherapy combined with antiangiogenic therapy as third‐ or further‐line therapy for stage IV non‐small cell lung cancer patients with ECOG performance status 2: A retrospective study

Article

作者: Liu, Hong-Zhi ; Tian, Li-Jun ; Yu, Ze-Shun ; Ning, Fang-Ling ; Li, Shuo ; Wang, Ming-Yue ; Li, Shu-Jing

Abstract:

Background:

Patients with Eastern Cooperative Oncology Group performance status (ECOG PS) 2 probably cannot tolerate chemotherapy or other antitumor therapies. Some studies have reported that immunotherapy combined with antiangiogenic therapy is well‐tolerated and shows good antitumor activity. However, the efficacy of this combination as a later‐line therapy in patients with ECOG PS 2 is unclear. This study evaluated the effectiveness and safety of this combination strategy as third‐ or further‐line therapy in stage IV non‐small cell lung cancer (NSCLC) patients with ECOG PS 2.

Methods:

In this retrospective study, patients treated with camrelizumab plus antiangiogenic therapy (bevacizumab, anlotinib, or recombinant human endostatin) were included. Objective response rate (ORR), disease control rate (DCR), progression‐free survival (PFS), overall survival (OS), quality of life (QOL) assessed by ECOG PS, and safety were analyzed.

Results:

Between January 10, 2019, and February 28, 2024, a total of 59 patients were included. The ORR was 35.6% (21/59) and the DCR was 86.4%. With a median follow‐up of 10.5 months (range: 0.7–23.7), the median PFS was 5.5 months (95% confidence interval [CI]: 3.8–7.3) and the median OS was 10.5 months (95% CI: 11.2–13.6). QOL was improved (≥1 reduction in ECOG PS) in 39 patients (66.1%). The most common Grade 3–4 treatment‐related adverse events were hepatic dysfunction (6 [10%]), hypertension (5 [8%]), and hypothyroidism (3 [5%]). There were no treatment‐related deaths.

Conclusions:

Third‐ or further‐line immunotherapy combined with antiangiogenic therapy is well‐tolerated and shows good antitumor activity in stage IV NSCLC patients with ECOG PS 2. Future large‐scale prospective studies are required to confirm the clinical benefits of this combination therapy.

2024-06-01·INVESTIGATIONAL NEW DRUGS

The efficacy and safety of continuous intravenous infusion of rh-endostatin combined with platinum-based doublet chemotherapy for advanced non-small-cell lung cancer

Article

作者: Gao, Min ; Jiang, Yunxiu ; Guo, Zihan ; Ji, Xiang ; Lu, Jiameng ; Liu, Xinyi ; Lu, Degan ; Zuo, Anli ; Yang, Shuran ; Su, Lin

Abstract:

Background:

Platinum-based doublet chemotherapy is commonly used in the treatment of non-small cell lung cancer (NSCLC). A growing body of evidence indicates that incorporating antiangiogenic agents into platinum-based chemotherapy may enhance the survival outcomes for NSCLC patients. However, the optimal administration protocol for intravenous recombinant human endostatin (rh-endostatin), an antiangiogenic agent, remains uncertain at present.

Aim:

This study aims to investigate the efficacy and safety of 5-d continuous intravenous infusion of rh-endostatin in combination with chemotherapy for patients with advanced NSCLC. The predictive biomarkers for this treatment regimen were further probed.

Methods:

This prospective, single-arm multicenter study enrolled a total of 48 patients with advanced NSCLC who were histologically or cytologically confirmed but had not received any prior treatment from January 2021 to December 2022. Prior to the chemotherapy, these patients received a continuous intravenous infusion of rh-endostatin (210 mg) over a period of 120 h, using an infusion pump. The chemotherapy regimen included a combination of platinum with either pemetrexed or paclitaxel, given in 21-day cycles. The primary endpoint of the study was median progression-free survival (mPFS), and the secondary endpoints included median overall survival (mOS), objective response rate (ORR), disease control rate (DCR), and assessment of adverse events (AEs).

Results:

The mPFS was 6.5 months (95% confidence interval (CI): 3.8–9.1 m) while the mOS was 12.3 months (95% CI: 7.6–18.5 m). The ORR and DCR was 52.1% and 75.0%, respectively. Leukopenia (52.1%), anemia (33.3%), and thrombocytopenia (20.8%) were the most common adverse effects and these toxicities were deemed acceptable and manageable. In addition, a correlation was noted between elevated serum carcinoembryonic antigen (CEA) levels and decreased PFS and OS.

Conclusions:

The incorporation of a 5-day continuous intravenous infusion of rh-endostatin into platinum-based doublet chemotherapy has demonstrated both safety and efficacy in the treatment of advanced NSCLC. Furthermore, the baseline serum levels of CEA may potentially function as a predictor for the efficacy of rh-endostatin when combined with chemotherapy in NSCLC patients.

ClinicalTrials.gov:

NCT05574998.

42

项与重组人血管内皮抑制素 (先声药业) 相关的新闻（医药）

2024-09-24

·正大天晴药业集团

正大天晴安罗替尼联合贝莫苏拜单抗对比化疗治疗非MSI-H或非dMMR复发性或转移性子宫内膜癌III期临床试验招募受试者

招募受试者正大天晴药业集团股份有限公司正在全国开展一项“评价盐酸安罗替尼胶囊联合TQB2450注射液对比化疗治疗非微卫星高度不稳定（非MSI-H）或非DNA错配修复缺陷（非dMMR）的复发性或转移性子宫内膜癌的随机、对照、开放、多中心III期临床试验”。这项研究已得到国家药品监督管理总局的批准（批件号：2021LP02007、2021LP02013、2021LP02014、2021LP02015）并通过中心伦理，现在全国招募受试者。试验药物简介 TQB2450注射液（通用名：贝莫苏拜单抗注射液）是正大天晴自主研发的一款全新序列的创新人源化PD-L1单克隆抗体，于2024年5月获国家药品监督管理局（NMPA）批准上市，首个适应症是联合盐酸安罗替尼胶囊、卡铂和依托泊甘用于广泛期小细胞肺癌（ES-SCLC）患者的一线治疗。 2024年2月，贝莫苏拜单抗联合盐酸安罗替尼胶囊治疗复发性或转移性子宫内膜癌的上市申请获CDE受理，并被纳入优先审评审批程序。主要入选标准（1）经组织病理学证实的复发性或转移性晚期子宫内膜癌；（2）既往接受1线含铂为基础的双药治疗失败。允许前期进行新辅助和/或辅助化疗（单用化疗、同步放化疗或者作为序贯疗法），如新辅助/辅助治疗期间或充分治疗结束后6个月以内出现疾病进展/复发，则可视为一线化疗治疗失败；（3）提供生物样本进行MMR/MSI状态检测，且检测结果为非微卫星高度不稳定（非MSI-H）或非DNA错配修复缺陷（非dMMR）；（4）无法进行手术/放疗根治的患者；（5）年龄：≥18周岁（签署知情同意书时）；ECOG PS评分：0-1分；预计生存期超过3个月；（6）至少具有一个可测量病灶（RECIST 1.1）；（7）主要器官功能良好。主要排除标准（1）既往使用过贝伐珠单抗、恩度、安罗替尼、阿帕替尼、仑伐替尼、索拉非尼、舒尼替尼、瑞戈非尼、呋喹替尼等抗血管生成药物或针对PD-1、PD-L1等相关细胞和免疫治疗药物；（2）研究治疗开始前2周内接受过NMPA批准药物说明书中明确具有抗肿瘤适应症的中成药（包括复方斑蝥胶囊、康艾注射液、康莱特胶囊/注射剂、艾迪注射液、鸦胆子油注射剂/胶囊、消癌平片/注射剂、华蟾素胶囊等）治疗；（3）病理提示有癌肉瘤（恶性mullerian混合肿瘤）、子宫内膜平滑肌肉瘤或其它高等级肉瘤，或子宫内膜间质肉瘤；（4）首剂试验药物治疗前1周内曾接受过针对子宫内膜癌的激素治疗；（5）研究治疗开始前4周内曾接受过手术、化疗、放疗或其它抗癌疗法（从末次治疗结束时间开始计算洗脱期）。口服靶向药不足 5 个药物半衰期；（6）有已知中枢神经系统转移和/或癌性脑膜炎的受试者；除非无症状，或接受过治疗且稳定，在脑转移治疗后至少2周未发现新发脑转移或脑转移扩大的影像学证据，并在研究治疗开始之前停止了类固醇或抗惊厥药物治疗至少14天；（7）3年内出现过或当前同时患有其它恶性肿瘤；（8）不能控制的需要反复引流的胸腔积液、心包积液或腹水（研究者判断）。研究中心信息如果您符合以上条件或有意向参加该项研究，请扫描下方二维码报名。正大天晴药业集团是集药品的科研、生产和销售为一体的创新型医药集团企业，员工14000多人，是国内抗肿瘤、肝病、呼吸领域的知名企业，位列中国医药工业百强榜第12位，为中国医药研发产品线最佳工业企业。正大天晴始终将科技创新作为企业可持续发展的重要战略，为积极研制创新和高品质药品不懈努力，重点打造肿瘤、肝病、呼吸等产品集群。公司年研发投入占销售收入的17%，在研项目148个，其中创新药80个，先后承担国家重大专项课题33项，累计有效申请及专利3080项，拥有有效授权专利1137项，形成了“上市一代、储备一代、研发一代”的良性格局。健康科技，温暖更多生命。为社会提供优质产品是我们不变的初心，正大天晴希望为患者提供更佳的健康解决方案，为提高公众健康水平与药品可及性不懈努力。注：以上数据来自正大天晴内部报表，统计时间截至2023年底

临床3期优先审批免疫疗法上市批准申请上市

2024-09-06

·药融云

先声药业与塔吉瑞合作，引进第三代ALK/ROS1抑制剂！

2024年9月2日，先声药业发布公告，先声再明与深圳市塔吉瑞生物医药有限公司（下称塔吉瑞）就临床阶段抗肿瘤候选药物ALK/ROS1双重受体酪氨酸激酶抑制剂TGRX-326订立合作协议。根据协议条款，先声再明将获得TGRX-326在中国大陆的独家商业化权益（包括但不限于对TGRX-326进行推广、相关策略的制订、调整及获得与此相关利益的权利等）。塔吉瑞将获得逾2000万美元首付款，并将向先声再明支付推广服务费。 TGRX-326是由塔吉瑞自主研发的第三代间变性淋巴瘤激酶（ALK）抑制剂，是一种强效、高选择性的ALK和c-ROS原癌基因1（ROS1）双重受体酪氨酸激酶（RTK）小分子抑制剂，对于ALK/ROS1融合基因阳性，以及包括 G1202R 在内的多种 ALK 耐药突变的非小细胞肺癌患者均具有极高的潜在治疗价值。 TGRX-326目前处于三期临床阶段。先声再明是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，2023年起独立运营，致力于以突破性治疗手段, 解决中国乃至全球肿瘤领域巨大的未满足临床需求。再明着力打造高价值创新研发管线，已上市产品组合包含科赛拉®、恩维达®、恩度®、恩立妥®4款创新药，正创造业绩快速增长曲线。塔吉瑞是一家专注于自主知识产权靶向抗癌药物研发的高科技医药研发公司，致力于挑战癌症的升级版——获得性耐药的医学难题。塔吉瑞自主搭建了前沿高效的小分子药物开发系列平台，坚持源头创新，具备化学药物设计、筛选、评价、优化等创新研发能力。成立至今，已累计获得包括中国、美国、欧洲、日本等区域在内的170 余项专利授权，并在中国及海外就部分药物管线开展多地临床。参考资料：先声药业内容来源于网络，如有侵权，请联系删除。

引进/卖出突破性疗法申请上市ASH会议

2024-09-03

·先声药业

先声再明Polθ抑制剂SIM0508获美国FDA批准进入临床研究

2024年8月29日，先声药业集团（2096.HK）旗下抗肿瘤创新药公司先声再明宣布，其自主研发的抗肿瘤候选药物－DNA聚合酶θ（Polθ）小分子抑制剂SIM0508已获得美国药品监督管理局（FDA）批准开展药物临床试验，拟用于治疗局部晚期/转移性实体瘤。 SIM0508是一种选择性靶向Polθ的强效小分子抑制剂，可通过抑制Polθ的活性，阻断MMEJ修复，进而选择性抑制HRD肿瘤细胞的增殖，并可与聚腺苷二磷酸核糖聚合酶(PARP)抑制剂或化疗药物联用，产生显著的协同增效作用。 SIM0508在临床前研究中表现出良好的口服药代动力学性质和安全性，未观察到明显的血液学毒性，提示其与PARP抑制剂或化疗药物联用产生的叠加毒性风险较低，有潜力成为一种治疗多种HRD实体瘤的抗癌新策略。其相关研究数据曾发表于2024年美国癌症研究协会（AACR）年会。目前，SIM0508已在中美两国获批进入临床研究。关于先声再明先声再明是先声药业集团旗下专注于抗肿瘤创新药研发、生产和商业化的生物医药公司，2023年起独立运营，致力于以突破性治疗手段, 解决中国乃至全球肿瘤领域巨大的未满足临床需求。再明着力打造高价值创新研发管线，已上市产品组合包含科赛拉®、恩立妥®、恩维达®、恩度®4款创新药，正创造业绩快速增长曲线。再明与全球合作伙伴的协同创新，为临床提供更有效的治疗手段，让更多肿瘤患者再现生机与光明。媒体联络：pr@zaiming.com

AACR会议申请上市突破性疗法

100 项与重组人血管内皮抑制素 (先声药业) 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	L01	DB06423

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
非小细胞肺癌	中国	山东先声生物制药有限公司	2005-09-12

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
恶性腹水	临床3期	中国	山东先声生物制药有限公司	2021-07-21
恶性胸腔积液	临床3期	中国	山东先声生物制药有限公司	2021-07-21
局部晚期非小细胞肺癌	临床3期	中国	江苏先声药业有限公司	2018-08-01
晚期结直肠腺癌	临床3期	中国	江苏先声药业有限公司	2018-07-01
晚期肺腺癌	临床2期	中国	江苏先声药业有限公司	2012-03-01
脑转移瘤	临床2期	中国	江苏先声药业有限公司	2011-06-01
食管癌	临床2期	中国	江苏先声药业有限公司	2011-05-01
黑色素瘤	临床2期	中国	江苏先声药业有限公司	2008-08-01
晚期非小细胞肺癌	临床1期	中国	江苏先声药业有限公司	2011-09-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


WCLC2024 人工标引	临床2期	非小细胞肺癌一线 driver gene-negative	29	Envafolimab and Rh-endostatin combined with platinum-based dual-agent chemotherapy	獵選壓夢願網顧憲鹽範(選夢廠鏇顧鑰艱構網衊) = 鹽艱壓觸鹽餘觸餘願鏇鑰蓋積窪願顧願襯鑰壓 (願鹽廠積觸鬱淵壓衊鏇, 76.8 ~ 109.4) 更多	积极	2024-09-09
NCT02907710 (phase III, ASCO2024) 人工标引	临床3期	晚期鼻咽癌	300	Endostar plus CCRT	鹹獵製蓋齋網齋廠繭窪(獵齋憲鬱糧繭繭衊艱齋) = 構膚鹹獵積鏇願鑰壓獵築鬱構築願衊顧憲簾蓋 (醖糧蓋衊獵廠構窪齋鏇 ) 更多	积极	2024-05-24
				CCRT alone	鹹獵製蓋齋網齋廠繭窪(獵齋憲鬱糧繭繭衊艱齋) = 夢築憲淵繭簾繭艱襯繭築鬱構築願衊顧憲簾蓋 (醖糧蓋衊獵廠構窪齋鏇 ) 更多
ESMO_ASIA2023	临床2期	局部晚期食管鳞状细胞癌	90	Endostar plus concurrent chemoradiotherapy (CCRT)	壓襯鏇願醖繭鹽網觸憲(觸壓憲鹽蓋鏇築簾選繭) = 夢願壓餘襯鏇製膚醖淵壓鏇鬱糧鏇鹹蓋繭鑰夢 (鑰壓窪鹽餘鏇網鬱衊鏇 ) 更多	积极	2023-12-02
				Concurrent chemoradiotherapy (CCRT)	憲範壓鏇選鏇齋鏇繭製(遞齋築膚窪網壓膚憲製) = 獵衊築製鑰獵構廠簾齋壓構鹽餘鑰醖製築蓋鹽 (範襯遞餘顧鑰夢淵鑰觸 ) 更多
ESMO2023 人工标引	临床2期	局部晚期食管鳞状细胞癌	92	Endostar+concurrent chemoradiotherapy	糧築襯願醖範繭遞繭鑰(壓鏇糧觸蓋鏇夢淵遞積) = 願鬱壓衊壓餘鑰廠淵鹽遞壓範餘壓觸蓋鏇簾願 (蓋蓋獵繭網鬱製窪選艱 ) 更多	积极	2023-10-23
				Concurrent chemoradiotherapy	糧築襯願醖範繭遞繭鑰(壓鏇糧觸蓋鏇夢淵遞積) = 遞襯築顧鏇糧襯膚衊齋遞壓範餘壓觸蓋鏇簾願 (蓋蓋獵繭網鬱製窪選艱 ) 更多
ESMO_GCC2023	N/A	局部晚期宫颈癌	41	Endostar combined with chemoradiotherapy	構獵醖衊淵繭網製觸觸(選蓋獵膚積淵膚齋窪簾) = 鑰製襯鑰觸衊襯鹽簾選繭鹽鑰襯夢窪夢醖鹽蓋 (遞衊觸衊鑰範艱衊願願 ) 更多	-	2023-02-23
				Chemoradiotherapy	構獵醖衊淵繭網製觸觸(選蓋獵膚積淵膚齋窪簾) = 鑰夢選醖觸窪鹽淵網簾繭鹽鑰襯夢窪夢醖鹽蓋 (遞衊觸衊鑰範艱衊願願 ) 更多
CSCO2022	N/A	肺癌 \| 恶性胸腔积液	78	顺铂	餘鹹衊獵獵遞顧遞觸夢(顧壓鹹網顧製壓壓廠壓) = 艱獵鑰窪選齋鹽簾鏇糧醖繭膚願鹹鏇廠襯夢艱 (鏇遞範鬱憲艱餘繭膚鑰 ) 更多	-	2022-09-21
CSCO2022	N/A	-	815	对照治疗组	築簾顧願遞築遞窪衊築(壓簾壓廠鏇憲選積獵遞) = 鹽壓鑰製積獵蓋衊繭廠鹹鏇艱選醖鏇餘衊鹹鬱 (淵淵蓋繭繭選獵壓壓壓 ) 更多	积极	2022-09-21
				恩度治疗组	築簾顧願遞築遞窪衊築(壓簾壓廠鏇憲選積獵遞) = 範鬱鹽製憲窪鹹簾鹽簾鹹鏇艱選醖鏇餘衊鹹鬱 (淵淵蓋繭繭選獵壓壓壓 ) 更多
CSCO2022	N/A	晚期鳞状细胞肺癌	19	重组人血管内皮抑制素联合阿法替尼及替吉奥	醖蓋蓋鑰簾鑰遞壓壓範(齋築鏇範憲壓糧蓋淵夢) = 没有与治疗相关的死亡报告遞獵積憲鹹齋構夢齋膚 (獵糧餘鑰鹹夢醖鏇選選 ) 更多	-	2022-09-21
WCLC2022	N/A	晚期非小细胞肺癌	27	Endostar + Camrelizumab + Chemotherapy	遞遞醖觸觸築鏇齋壓鏇(製鹽鬱膚夢齋鬱鹹襯範) = 積鏇製襯齋築鑰鹹壓衊窪築製窪選遞遞範網願 (膚齋積齋廠顧鏇壓構鏇 ) 更多	-	2022-08-06
NCT03797625 (Pubmed \| Oncologist) 人工标引	临床2期	晚期食管鳞状细胞癌二线	50	Irinotecan+Cisplatin+Rh-Endostatin	鑰獵憲顧鹹鑰襯膚繭範(醖積製築艱窪淵鏇網網) = 廠積淵膚淵壓糧夢築顧鏇觸製齋艱網積選鬱鹹 (選網衊鏇繭構願餘鏇醖, 3.19 ~ 5.49) 更多	积极	2022-04-05